Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q4 FY2019 Earnings Presentation
10 slides from Aurobindo Pharma's earnings presentation, May 28, 2019
Slide 1: Letter to stock exchanges: Investors/Analysts Presentation
~ AUROBINDO May 28,2019 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI ·400 051 MUMBAI ·400 001 Company Code No. AUROPHARMA
Slide 2: Leading Vertically Integrated Generic Player – Q4FY18-19 Earnings Presentation
LEADING VERTICALLY INTEGRATED GENERIC PLAYER Q4FY18-19 Earnings Presentation
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any
Slide 4: Consolidated Financial Highlights – Q4FY19 & FY19
Consolidated Financial Highlights – Q4FY19 & FY19 Q4FY19 Performance • Revenue from operations at INR 5,292.2 crore, witnessed a strong growth of 30.7% YoY • EBIDTA before forex and other income at INR 1,060.3 crore, an increase of 31.9% YoY; EBITDA margin is at 20.0% • Net Profit after JV share, mi
Slide 5: Business Highlights – Q4FY19 & FY19
Business Highlights – Q4FY19 & FY19 US Formulations • In FY19, US revenue increased by 21.3% YoY to INR 9,030.7 crore compared to INR 7,442.1 crore in FY18, accounting for 46.2% of consolidated revenue. On constant currency basis, revenue grew by 11.8% YoY to US$ 1,292 million • US revenue for Q4FY1
Slide 6: US Filings Snapshot
US Filings Snapshot Cumulative ANDA Filings and Approvals Addressable 541 Therapy ANDAs Market Size 478 (US$ Bn) 138 Anti Diabetic 19 9.2 As per IQVIA Mar 2019, 429 398 117 ARV** 42 5.7 376 26 addressable Market at US$ 115 34 CNS 95 24.8 97.8 Bn including ~US$ 65.7 147 183 38 Controlled Substances 1
Slide 7: Consolidated Financial Performance – Q4FY19
Consolidated Financial Performance – Q4FY19 Q4 Q4 % Value INR Cr Revenue from Operations - Breakup FY19 FY18 Chg Value in INR Cr Q4FY19 Q4FY18 % Chg Formulations 4,373.6 3,248.6 34.6 USA 2,481.1 1,738.8 42.7 API 916.8 799.6 14.6 EU 1,311.8 1,151.6 13.9 Formulations % of sales 82.7% 80.2% Growth mark
Slide 8: Consolidated Financial Performance – FY19
Consolidated Financial Performance – FY19 Value INR Cr FY19 FY18 % Chg Revenue from Operations - Breakup Formulations 16,157.0 13,533.2 19.4 Value in INR Cr FY19 FY18 % Chg USA 9,030.7 7,442.1 21.3 API 3,403.0 2,962.2 14.9 EU 4,960.2 4,354.4 13.9 Formulations % of sales 82.6% 82.0% Growth markets 1,
Slide 9: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-16 Mar-17 Mar-18 Dec-18 Mar-19 Closing Rate1 US$ = 66.25 64.85 65.17 69.775 69.155 INR Fx Loan restated in 4,956.7 3,121.5 4,766.9 5,381.8 6,959.0 748 481 731 771 1,006 INR Rupee Loan 46.9 244.8 4.1 289.7 8.1 Sales Tax Deferment 41.9 0.0 0.0 0.0 0.
Slide 10: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725401 +91 98486 67906 Email: ir@aurobindo.com Corporate Office: Water Mark Building, Level-6, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Registered Of